Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12220.158 | 1.0633 | 1.3064 | 0.4308 | |
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12220.158 | 0.9889 | 0.9486 | 0.4308 | |
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12220.158 | 0.8500 | 0.3716 | 0.4308 | |
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12220.158 | 0.8321 | 0.3053 | 0.4308 | |
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12220.158 | 0.3683 | -0.8032 | 0.4308 | |
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12220.158 | 0.0198 | -0.9998 | 0.4308 | |
| MX1 | Unknown | Unknown | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12220.158 | 0.0122 | -0.9999 | 0.4308 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11851.158 | 0.8938 | 0.8481 | 1.4217 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11851.158 | 0.9686 | 0.9556 | 1.4217 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11851.158 | 0.8739 | 0.8191 | 1.4217 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11851.158 | 0.5467 | 0.3079 | 1.4217 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11851.158 | 0.1342 | -0.5130 | 1.4217 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11851.158 | 0.0814 | -0.6574 | 1.4217 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11851.158 | 0.0722 | -0.6851 | 1.4217 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11851.158 | 0.2615 | -0.2216 | 1.4217 | |
| SK-BR-3 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11851.158 | 0.0079 | -0.9334 | 1.4217 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12428.165 | 1.0079 | 1.0224 | 0.7051 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12428.165 | 0.9914 | 0.9756 | 0.7051 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12428.165 | 0.9145 | 0.7619 | 0.7051 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12428.165 | 0.8057 | 0.4721 | 0.7051 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12428.165 | 0.7791 | 0.4037 | 0.7051 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12428.165 | 0.7419 | 0.3096 | 0.7051 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12428.165 | 0.5563 | -0.1295 | 0.7051 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12428.165 | 0.4351 | -0.3856 | 0.7051 | |
| SUM1315MO2 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12428.165 | 0.0094 | -0.9973 | 0.7051 |